Iressa (Gefitinib)

Phase 2Terminated

0 views this week 0 watching💤 Quiet

Interest: 27/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Brain Neoplasms

Conditions

Brain Neoplasms, Non Small Cell Lung Cancer

Trial Timeline

Jul 1, 2004 → Feb 1, 2006

NCT ID

NCT00234442

About Iressa (Gefitinib)

Iressa (Gefitinib) is a phase 2 stage product being developed by AstraZeneca for Brain Neoplasms. The current trial status is terminated. This product is registered under clinical trial identifier NCT00234442. Target conditions include Brain Neoplasms, Non Small Cell Lung Cancer.

What happened to similar drugs?

5 of 18 similar drugs in Brain Neoplasms were approved

Approved (5) Terminated (2) Active (13)

✅ExenatideAstraZenecaApproved

✅RivastigmineNovartisApproved

✅Genotropin (PN-180,307) SomatropinPfizerApproved

✅Genotropin + PlaceboPfizerApproved

✅Dotarem® + Gadovist®/Gadavist®GuerbetApproved

🔄Nivolumab + TemozolomideOno PharmaceuticalPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00169221	Phase 2	Terminated	Sep 1, 2005	Jul 1, 2011	Head and Neck Cancer
NCT00234442	Phase 2	Terminated	Jul 1, 2004	Feb 1, 2006	Brain Neoplasms
NCT00234468	Phase 3	Terminated	Jan 1, 2004	Aug 1, 2007	Non Small Cell Lung Carcinoma
NCT00233636	Phase 2	Withdrawn	Jul 1, 2003	—	Head and Neck Cancer

Competing Products

20 competing products in Brain Neoplasms

See all competitors

Product	Company	Stage	Hype Score
Abemaciclib + Endocrine therapy	Eli Lilly	Phase 1/2	39
Duloxetine + Sugar pill	Eli Lilly	Phase 2	27
Neurosteroid enantiomer	Oragenics	Phase 2	32
Patritumab deruxtecan	Daiichi Sankyo	Phase 2	27
filgrastim + exatecan mesylate	Daiichi Sankyo	Phase 1	29
Eribulin Mesylate	Eisai	Phase 1	29
Pembrolizumab + Lenvatinib	Eisai	Phase 2	42
Palonosetron (Aloxi) and Dexamethasone	Eisai	Phase 2	27
GLIADEL	Eisai	Phase 2	35
Nivolumab + Temozolomide	Ono Pharmaceutical	Phase 3	40
Nivolumab + Temozolomide	Ono Pharmaceutical	Phase 3	40
Prexasertib + Cyclophosphamide + Gemcitabine + filgrastim + peg-filgrastim	Eli Lilly	Phase 1	29
abemaciclib + abemaciclib	Eli Lilly	Phase 2	39
JNJ-17299425	Johnson & Johnson	Phase 2	27
ABT-888	AbbVie	Phase 1	29
Veliparib + Placebo	AbbVie	Phase 2	35
Trastuzumab deruxtecan	AstraZeneca	Phase 2	42
Exenatide	AstraZeneca	Approved	43
AZD5213	AstraZeneca	Phase 1	29
Vorinostat	Merck	Phase 1	29